MTOR and neoplasm: A recent investigation in medulloblastoma tissue, showed that a tumor driving pathway, e.g., mTOR activation can cross-talk with indolamin-desoxygenase (IDO) expression, which consecutively induces Treg cell expansion and immunosuppression of tumor-specific immune responses (25).